Aldeyra Therapeutics, Inc. — Q1 2014 Form 10-Q Summary
Business context and reporting period
The unaudited filing covers the quarter ended March 31, 2014. Aldeyra was a development-stage biotechnology company focused on aldehyde-trapping therapies, principally NS2, for Sjögren-Larsson Syndrome and acute anterior uveitis. The company had no approved products and no product revenue.
Management reported plans to initiate a Phase II/III SLS trial and a Phase II acute anterior uveitis trial in 2014, with data then expected in the second half of 2015. The company completed its initial public offering on May 7, 2014, after the quarter ended.
Key financial metrics
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $444,278 | $150,233 |
| General and administrative expense | $800,646 | $141,305 |
| Loss from operations | $1,244,924 | $291,538 |
| Net income (loss) | $401,773 | $(3,974,933) |
| Net loss attributable to common stockholders | $(13,237) | $(4,098,092) |
| Net cash used in operating activities | $(1,063,892) | $(298,021) |
| Cash and cash equivalents at period-end | $2,145,621 | $1,676,053 |
The reported Q1 2014 net income was not indicative of operating profitability. It included approximately $1.8 million of non-cash income from a decrease in the fair value of preferred-stock warrant liabilities. The company continued to incur operating losses and had an accumulated development-stage deficit of $40.9 million.
At March 31, 2014, total assets were $2.9 million, total liabilities were $4.0 million, redeemable convertible preferred stock was $38.5 million, and stockholders’ deficit was $39.6 million. Debt included approximately $1.4 million outstanding under a secured credit facility and $155,097 of convertible notes payable to related parties, before applicable discounts and accrued interest.
Material changes versus the prior comparable period
- Research and development expense increased $294,045, or approximately 196%, primarily due to higher external development expenditures and stock-based compensation.
- General and administrative expense increased $659,341, or approximately 467%, due primarily to higher headcount-related compensation, legal and audit costs, and stock-based compensation.
- Operating cash use increased to $1.1 million from $0.3 million, reflecting higher research and development and general and administrative spending.
- Financing cash flow changed from $750,436 provided in Q1 2013 to $52,841 used in Q1 2014. The Q1 2014 use primarily represented payments for deferred IPO costs.
- Cash declined $1.1 million during Q1 2014, from $3.3 million at December 31, 2013 to $2.1 million at March 31, 2014.
- The fair value of preferred-stock warrant liabilities declined from $3.5 million at December 31, 2013 to $1.8 million at March 31, 2014, producing non-cash other income of approximately $1.8 million.
Liquidity, outlook, risks, and unusual items
The company had drawn the full $1.5 million available under its Square 1 Bank credit facility. The facility was secured by company assets, including intellectual property, carried a 6.50% interest rate, and required interest-only payments through November 2014 before scheduled principal payments through November 2016.
On May 7, 2014, the company completed its IPO of 1.5 million shares at $8.00 per share and received net proceeds of approximately $11.0 million. The preferred stock converted into 3,642,799 common shares, preferred-stock warrants were net exercised and converted into 74,001 common shares, and the related-party convertible note converted into 21,250 common shares. Management stated that available cash after the IPO was expected to fund operations through the end of 2015, but additional capital would be required for later-stage development and commercialization.
Management estimated approximately $5.0 million would be required to complete the clinical trials and related research and development expected to begin in 2014. The company warned that it would require substantial additional financing and that financing may be unavailable or dilutive.
- NS2 had completed a Phase I trial in 48 healthy volunteers as an eye drop and was reported to be safe and well tolerated in that setting, but efficacy had not been demonstrated in patients.
- Separate regulatory submissions and additional preclinical work were required for the planned SLS and uveitis programs; the company had not yet submitted an IND for topical dermatologic treatment of SLS.
- Key risks included clinical or regulatory failure, delays in enrollment or trial execution, uncertain efficacy and safety, reliance on contract research organizations and manufacturers, intellectual-property challenges, competition, and dependence on key personnel.
- The company had a license agreement requiring potential milestone payments of up to $2.15 million and future royalties upon commercialization.
- No legal proceedings were reported. No material indemnification claims were outstanding, and no liability was recorded for executive termination benefits because occurrence was not considered likely.
- Management stated that disclosure controls were effective as of March 31, 2014, while the risk factors disclosed a material weakness in internal controls related to non-routine complex transactions, stock-based compensation, and related disclosures.
Important facts for investors to verify
- Confirm the post-quarter IPO proceeds, share issuance, preferred-stock conversions, warrant exercises, and resulting capitalization.
- Reconcile reported net income with operating performance by excluding the non-cash fair-value gain on warrant liabilities.
- Assess cash-burn trends against the stated expectation that cash would fund operations through the end of 2015.
- Verify the timing, regulatory status, enrollment, costs, and results of the planned NS2 clinical trials.
- Review the terms, collateral, covenants, and repayment schedule of the secured credit facility.
- Monitor the company’s remediation of the disclosed internal-control material weakness.
- Evaluate future financing needs, potential dilution, license milestones and royalties, and the risk that NS2 may never receive regulatory approval or generate revenue.